‹ Back

Improving Intravenous Cannulation Success in Obese Diabetic Patients: The Role of Near-Infrared Vein Viewer Technology

 

 

Type 2 Diabetes (T2DM) is a growing health issue in Indonesia, with a prevalence of around 6% to 10% of the population. One of the challenges in treating diabetes patients, especially those with obesity, is the difficulty in performing intravenous (IV) cannulation, which is crucial for administering medication and fluid replacement.

 

Challenges in IV Cannulation for Obese Diabetic Patients

 

Obesity can worsen insulin resistance in diabetes patients and make blood vessels harder to locate due to excess subcutaneous fat. This makes the IV procedure more difficult, increasing the risk of complications such as hematomas and failed attempts at IV insertion.

 

Traditionally, medical staff rely on techniques such as tourniquet application or manual palpation to locate blood vessels. However, these methods are not always effective, especially in patients with a high body mass index (BMI). Difficulty in finding blood vessels in these patients can lead to multiple failed attempts, causing discomfort and prolonging the procedure.

 

"Did you know? There is now a faster and more accurate way to perform IV cannulation in obese patients, without the risk of repeated complications!"

 

Enter Near-Infrared Vein Viewer Technology

 

 

Near-infrared (NIR) vein viewer technology, such as the ZENMED+ Vein Viewer Vision, uses NIR light to illuminate blood vessels, making them more visible even in obese patients. Recent research in Baghdad has shown that this technology improves the success rate of IV cannulation.

 

Key Findings from the Study

 

The results from the study are promising.

 

"60.9% of patients using the NIR vein finder technology successfully had IV cannulation on the first attempt, compared to only 15.2% in the traditional method."

 

Additionally, the average procedural time for the intervention group was much shorter (53.2 seconds) compared to the control group (94.3 seconds). This indicates that the NIR vein finder technology can reduce the time and effort needed for successful IV cannulation, which is highly beneficial for both patients and medical staff.

 

.

The Benefits of Near-Infrared Vein Viewer Technology

 

The use of NIR vein finders can make a significant difference in the management of obese diabetic patients. The device offers several advantages:

 

Increased Success Rate:

 

By improving vein visibility, the NIR vein finder reduces the number of attempts needed for cannulation, leading to a higher success rate on the first attempt.

 

Reduced Procedural Time:

 

The technology helps healthcare providers locate veins more quickly, decreasing the overall time spent on the procedure and minimizing patient discomfort.

 

Improved Patient Experience:

 

Fewer failed attempts mean less pain, stress, and anxiety for patients, which can improve their overall hospital experience.

 

Reduced Healthcare Costs:

 

Faster and more efficient procedures mean less time spent in the hospital, potentially reducing treatment costs and improving patient throughput.

 

ZENMED+ Vein Viewer Vision : The first in Indonesia 

 

 

ZENMED+ Vein Viewer Vision uses near-infrared light technology to facilitate the visualization of blood vessels in patients with challenging anatomies, such as those with obesity-related diabetes. With this capability, the device enhances venipuncture accuracy, increases the chances of first-attempt success, and reduces discomfort and the risk of complications. As the first vein finder device produced in Indonesia, Vein Viewer Vision is a significant breakthrough in IV cannulation procedures, providing greater comfort for patients and high efficiency for healthcare professionals.

 

Want to see how ZENMED+ Vein Viewer Vision can improve your patient care? Contact us for a live demo or visit our website for more information.

 

Referensi

1. Al-Saadi, S.F. et al. (2022) ‘Effect of near-infrared vein finder technology on success rate of cannulation in obese diabetic patients’, Shiraz E-Medical Journal, 23(7). doi:10.5812/semj-120908.